Favrille wins fast-track designation for cancer drug Favld

Favrille has won the FDA's fast-track designation for Favld, a treatment for follicular B-cell non-Hodgkin's lymphoma following Rituxan. An ongoing Phase III trial of Favld should produce data on secondary endpoints late this year while primary endpoint data is expected in the second half of 2007. "This decision by the FDA has the potential to save us valuable time in the regulatory approval process, and also serves as an important acknowledgment of the potential for FavId in the treatment of B-cell follicular NHL," John P. Longenecker, Ph.D., CEO of Favrille.

- read this AP report for more information